Bristol-Myers Squibb

FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
Endpoints
FDA
Bristol-Myers Squibb
Opdivo
clinical trials
Multiple Myeloma
Flag link:
Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Flag link:
Bristol-Myers, Pfizer continue to build case for Eliquis
Bristol-Myers, Pfizer continue to build case for Eliquis
BioPharma Dive
Bristol-Myers Squibb
Pfizer
Eliquis
blood thinners
Flag link:
Pharma Stocks That Could Move On New Data
Pharma Stocks That Could Move On New Data
Barron's
pharma stocks
AbbVie
Bayer
Novartis
Bristol-Myers Squibb
Eli Lilly
European Society of Cardiology
Flag link:
An analysis of 2017 first half for pharmaceutical industry
An analysis of 2017 first half for pharmaceutical industry
GoInPharma
pharma industry
Pfizer
Sanofi
GSK
Roche
Celgene
Bristol-Myers Squibb
Flag link:
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
Market Realist
Opdivo
Bristol-Myers Squibb
Flag link:
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy
Bristol-Myers Squibb
kidney cancer
Opdivo
Yervoy
Flag link:
A Supreme Court pharma case deals consumers a big loss
A Supreme Court pharma case deals consumers a big loss
Stat
Supreme Court
consumers
Plavix
Bristol-Myers Squibb
Flag link:
Pharma's giants, new and old, tell more tales than their numbers show
Pharma's giants, new and old, tell more tales than their numbers show
Fierce Pharma
Big Pharma
JNJ
Pfizer
GSK
Roche
Novartis
Sanofi
Bristol-Myers Squibb
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff
Fierce Pharma
Bristol-Myers Squibb
HIV
layoffs
patent cliff
Reyataz
Sustiva
Flag link:
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Endpoints
Bristol-Myers Squibb
IFM Therapeutics
oncology
M&A
Flag link:
Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward
Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward
Forbes
Bristol-Myers Squibb
Opdivo
clinical trials
Flag link:
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Motley Fool
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval
Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval
Fierce Pharma
Bristol-Myers Squibb
Opdivo
colorectal cancer
Merck
Keytruda
Flag link:
Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases
Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases
Fierce Pharma
Bristol-Myers Squibb
Pfizer
Eliquis
bloodthinners
Flag link:
Why Clovis Oncology Tumbled 13.5% Today
Why Clovis Oncology Tumbled 13.5% Today
Motley Fool
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Flag link:
Bristol-Myers and Clovis will partner for cancer combination trials
Bristol-Myers and Clovis will partner for cancer combination trials
Marketwatch
clinical trials
Bristol-Myers Squibb
Clovis Oncology
Opdivo
Rubraca
Flag link:
Bristol shrugs off comparisons to MYSTIC
Bristol shrugs off comparisons to MYSTIC
BioPharma Dive
AstraZeneca
Bristol-Myers Squibb
Mystic
immuno-oncology
Opdivo
Flag link:
AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers
AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers
TheStreet.com
AstraZeneca
clinical trials
Mystic
Bristol-Myers Squibb
Opdivo
Flag link:

Pages